Navigation Links
MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments
Date:5/12/2008

his combined with a variety of relevant clinical papers, training materials and content gives these professionals access to information and products that they otherwise would have difficulty accessing.

Additional information can be found at http://www.mgtci.com.

All forward-looking statements are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission.

Investor & Media enquiries:

KCSA Strategic Communications

Todd Fromer / Garth Russell

Tel: +1 212-896-1215 / 212-896-1250

tfromer@kcsa.com / grussell@kcsa.com


'/>"/>
SOURCE MGT Capital Investments, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Launch of Fountain Healthcare Partners, a Life Science Venture Capital Firm
2. Vernalis and Paul Capital Healthcare Sign euro 18.4 Million Financing Agreement
3. SPO Medical Retains American Capital Ventures for Investor Relations Services
4. MichBio Will Host Workshop on Capital Formation Prior to April 22 Annual Meeting
5. CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
6. Powersafe Technology Corp. Recapitalizes, Executes Merger Agreement with Amplification Technologies, and Invests in Amplification
7. RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner
8. Biotech Avoids Fall Out From Tough Quarter for Capital Markets
9. Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Pharmasset Receives $10 Million of Working Capital

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...-FirstCall/ -- ,, 3Q09 Corporate Highlights:...arketing Authorization to Astellas Pharma Europe L...iness activities Expanded management team to incl...ctor, Commercial Operations Appointed Bradford S....chairman , Upcoming 2009 Milestones: ,...
(Date:11/6/2009)...rowhead’s 2010 Personalized Medicine Partner...bruary 22-24, 2010 in Philadelphia, has been annou...ht key issues in forming partnerships and engage t... Minneapolis, MN (PRWEB) Nove...2010 Personalized Medicine Partnerships Conference...
(Date:11/5/2009)... -- DSM Pharmaceutical Products today announced th...ix, Saint Jean D,Illac, France, where DSM will be ...er for Galenix commercial products on a global bas...ness development opportunities co-marketing Galeni...h of Galenix in drug product development and clini...
(Date:11/5/2009)...Call/ -- Transgenomic, Inc. (OTC Bulletin Board: T...rter ended September 30, 2009. The Company,s finan...ow. ,, Third Quarter 2009 ,, The Company r...for the third quarter of 2009 as compared to a net... quarter of 2008. ,, Net sales were $5.0 milli...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...sleading information, SOUTH SAN FRANCISCO, Calif....TC Bulletin Board: VXGN.OB), (Logo: http://ww... Dear Stockholders, On March 19th, MedCap Managem...ed a press release entitled "MedCap Urges Vote Aga...gies". We believe this release, one of,MedCap,s in...
...yland physicists have shown that in graphene the i...ell a material conducts electricity, is higher tha...aphene, a single-atom-thick sheet of graphite, is ...ctors and metals. , Their results, published onli...that graphene holds great promise for replacing co...
...ical and biotechnology research companies invested...and development of new life-changing,medicines and... 2006,according to analyses by the Pharmaceutical ...Burrill & Company. The release of the report coinc...ves today., This record R&D investment reflects t...
Other Biology Technology:VaxGen Issues Rebuttal to MedCap Letter 2VaxGen Issues Rebuttal to MedCap Letter 3VaxGen Issues Rebuttal to MedCap Letter 4VaxGen Issues Rebuttal to MedCap Letter 5VaxGen Issues Rebuttal to MedCap Letter 6VaxGen Issues Rebuttal to MedCap Letter 7VaxGen Issues Rebuttal to MedCap Letter 8VaxGen Issues Rebuttal to MedCap Letter 9VaxGen Issues Rebuttal to MedCap Letter 10VaxGen Issues Rebuttal to MedCap Letter 11UM physicists show electrons can travel over 100 times faster in graphene than in silicon 2UM physicists show electrons can travel over 100 times faster in graphene than in silicon 3R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007 2R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007 3
(Date:11/6/2009)...a.Registration is now open for the Society of Inte...l Oncology (IO) Therapies" Webinar, which will pro...atheter treatment of liver tumors, kidney tumor ab...organization of physicians, scientists and allied ... health through pioneering advances in image-guide...
(Date:11/6/2009)...ing ants generally live in harmony with their arbo...ey run out of space in their trees of choice, the ... The research, published in the November issue of ...t that ants bore into live trees, and it reopens a...ants and plants. , Ants and certain species of p...
(Date:11/6/2009)...IA (November 06, 2009) The Monell Center and the ...the Beijing International Meeting on Taste and Sme...with the CAS, the meeting will be the first intern...hina. , Alan Leshner, Chief Executive Officer, A... and Executive Publisher of Science magazine, will...
Breaking Biology News(10 mins):Society of Interventional Radiology hosts oncology therapies Webinar, offers resources 2Ants are friendly to some trees, but not others 2Monell Center joins with CAS to host Beijing meeting on taste and smell research 2GSA showcases groundbreaking aging research slated for Atlanta meeting 59757 1GSA showcases groundbreaking aging research slated for Atlanta meeting 59757 2GSA showcases groundbreaking aging research slated for Atlanta meeting 59757 3GSA showcases groundbreaking aging research slated for Atlanta meeting 59757 4Global warming may spur increased growth in Pacific Northwest forests 10416 1Global warming may spur increased growth in Pacific Northwest forests 10416 2Global warming may spur increased growth in Pacific Northwest forests 10416 3Caltech scientists create robot surrogate for blind persons in testing visual prostheses 10414 1Caltech scientists create robot surrogate for blind persons in testing visual prostheses 10414 2Caltech scientists create robot surrogate for blind persons in testing visual prostheses 10414 3
... microbiologist Matthew Fields spends his days stu...r granted. , Fields studies the physiology and be...nhabited virtually every square inch of the earth,...crobes have global impact," Fields said. "They gro...ower in numbers." , Fields is particularly intere...
... a frog that lives near noisy springs in central C...ies, much like the tuner on a radio can shift from...ample of an animal that can actively select what f...indings, from a collaborative effort led by the Un...nia at Los Angeles, appear this week in Proceedin...
...hing is banned can have benefits that extend beyon...ned to protect, according to new evidence from Aus...2nd issue of Current Biology , a Cell Press publi...arge, predatory crown-of-thorns starfish ( Acantha...cur less often in protected zones, although they d...
Other Biology News:MSU researcher uses grant to study little-known but largely useful microbes 2Ultrasonic frogs can tune their ears to different frequencies 2Ultrasonic frogs can tune their ears to different frequencies 3Fishing ban guards coral reefs against predatory starfish outbreaks 2
...analytical to medium scale affinity purification o...ectors. Sufficient reagents are provided for purif...or denaturing conditions. Crude samples are incuba...ains STag fusion proteins. After unbound proteins ...
Anti-S-100 protein, ab heterodimer Monoclonal Antibody, Unconjugated from HyTest Ltd.
...st extract, 5 ,Sodium chloride, 10 ,Agar, 12 ,...TG, 0.03 ,-Gal is a patented, water soluble, au...e. The enzymatic hydrolysis of S-Gal by -galactosi... colonies grown in the presence of S-gal are much ...
Mouse Anti-Human S-100 alpha/beta chain Monoclonal Antibody, Unconjugated, Clone 8B10 from Santa Cruz Biotechnology, Inc.
Biology Products: